Breztri is a prescription inhaler used as a long‑term maintenance treatment to help adults with chronic obstructive pulmonary disease (COPD) breathe more easily and reduce flare‑ups, not as a quick‑relief “rescue” inhaler.

What is Breztri?

Breztri Aerosphere is a triple‑therapy inhaler that combines three medicines in one device:

  • Budesonide (an inhaled corticosteroid)
  • Glycopyrrolate (a long‑acting muscarinic antagonist, LAMA)
  • Formoterol (a long‑acting beta agonist, LABA)

It is taken every day, usually as 2 inhalations twice daily, to keep symptoms under control over time.

How does Breztri work?

Each ingredient targets breathing problems in a different way:

  • Budesonide: reduces inflammation and swelling inside the airways. This helps calm chronic irritation in COPD.
  • Glycopyrrolate: blocks muscarinic (M3) receptors, relaxing airway muscles and keeping airways more open for longer.
  • Formoterol: stimulates beta‑2 receptors in the lungs to open the airways and improve airflow.

Together, this triple action is designed to improve lung function, ease day‑to‑day breathlessness, and reduce COPD exacerbations.

What is Breztri used for?

Right now, Breztri is:

  • Approved as a long‑term maintenance treatment for adults with COPD (including chronic bronchitis and/or emphysema) in more than 80 countries, including the US, EU, China, and Japan.
  • Not a rescue inhaler for sudden shortness of breath or asthma attacks.

Recent large Phase III trials (KALOS and LOGOS) showed that Breztri improved lung function and reduced exacerbations in people with uncontrolled asthma compared with standard dual inhalers (ICS/LABA, like Symbicort). Based on these results, regulatory filings to approve Breztri for asthma are under review in major regions.

Who might be prescribed Breztri?

Doctors may consider Breztri for:

  • Adults with COPD who still have symptoms or frequent flare‑ups despite using other inhalers.
  • People needing both anti‑inflammatory treatment and stronger, long‑acting bronchodilation in a single inhaler for convenience and adherence.

In some real‑world and forum discussions, clinicians have also used Breztri in patients whose asthma remained uncontrolled on medicines like Symbicort, although asthma use is still being formally reviewed by regulators.

Common side effects and safety notes

Reported common side effects include:

  • Upper respiratory infections, pneumonia, flu‑like illness
  • Cough, sore throat, sinus irritation
  • Back or muscle pain, muscle spasms
  • Urinary tract infection, diarrhea
  • Oral thrush (yeast infection in the mouth and throat)

Because of the steroid component, people are advised to rinse their mouth and spit after each use to help prevent thrush. Like other long‑acting bronchodilators, Breztri may not be suitable for everyone, especially people with certain heart, eye (glaucoma), or urinary conditions, so it must be prescribed and monitored by a health professional.

Latest news and “trending” context

  • 2026 trial updates: The KALOS and LOGOS Phase III trials in uncontrolled asthma showed “statistically significant and clinically meaningful” improvements with Breztri over dual ICS/LABA therapies, with no new major safety signals detected.
  • Regulatory momentum: Based on these results, filings to extend Breztri’s indication to asthma are being reviewed across major global markets.
  • Community/Forum chatter: On patient forums and Reddit, some users report being switched to Breztri when other inhalers (like Symbicort) were not working well, and others ask about experiences, side effects, and whether it helps with conditions like bronchiectasis.

Many forum posts describe Breztri as a “triple” inhaler that feels stronger than their previous inhaler, but experiences vary—some feel much better, others notice side effects or little change.

Quick fact sheet (HTML table)

[1][5] [3][5][1] [5][9][1] [4][9] [2][6][10] [9][4]
Question Short Answer
What is Breztri? A triple‑therapy maintenance inhaler for adults with COPD.
What medicines are inside? Budesonide (ICS), Glycopyrrolate (LAMA), Formoterol (LABA).
Main use today Long‑term treatment to improve breathing and reduce COPD flare‑ups.
Is it for sudden attacks? No, it is not a rescue inhaler.
Asthma status Promising Phase III asthma data; regulatory approval for asthma under review.
Common side effects Upper respiratory infections, pneumonia, cough, thrush, muscle pain/spasms.

Bottom note

Information gathered from public forums or data available on the internet and portrayed here.